Artelo Biosciences, Inc. (ARTL)
| Market Cap | 3.05M -52.0% |
| Revenue (ttm) | n/a |
| Net Income | -12.67M |
| EPS | -11.38 |
| Shares Out | 4.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,399,759 |
| Open | 0.6589 |
| Previous Close | 0.6610 |
| Day's Range | 0.6184 - 0.6798 |
| 52-Week Range | 0.5200 - 28.1400 |
| Beta | -0.07 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About ARTL
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company’s product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and inso... [Read more]
Financial Performance
Financial StatementsNews
Artelo Biosciences Inc trading halted, news pending
19:50 EDT Artelo Biosciences (ARTL) Inc trading halted, news pending
Artelo Biosciences announces 1-for-9 reverse stock split
Artelo Biosciences (ARTL) announced a 1-for-9 reverse stock split of the company’s common stock. The company’s common stock will begin trading on a split-adjusted basis on Nasdaq commencing at the…
Artelo Biosciences Announces Reverse Stock Split
Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026 Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026
Artelo secures Japan patent allowance for ART27.13 commercial formulation
Artelo Biosciences (ARTL) announced that the Japanese Patent Office has issued a notification of allowance with a decision to grant for the company’s patent application covering the intended commercia...
Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13
SOLANA BEACH, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signal...
Artelo Biosciences receives notice of allowance from USPTO
Artelo Biosciences (ARTL) announced that the United States Patent and Trademark Office has issued a notice of allowance for a U.S. patent application covering the intended commercial formulation of AR...
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
The Patent Claims are for the Intended Commercial Formulation of ART27.13 Expected to Extend Patent Protection for ART27.13 through 2041 SOLANA BEACH, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Artelo ...
Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
SOLANA BEACH, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signali...
Artelo Biosciences Quarterly report: Q2 2026
Artelo Biosciences has published its Q2 2026 quarterly earnings report on August 13, 2026.
Artelo Biosciences Earnings release: Q2 2026
Artelo Biosciences released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Artelo Biosciences doses first patient in DREAM study
Artelo Biosciences (ARTL) announced the first patient has been dosed in the DREAM study, which will evaluate the effects of Artelo’s orally administered synthetic cannabinoid, ART27.13, in patients wi...
Artelo Biosciences Transcript: AGM 2026
The meeting covered director elections, an increase in authorized shares, and approval for a significant equity issuance. All proposals passed, and no questions were raised by shareholders during the Q&A session.
Artelo Biosciences announces new ART26.12 data
Artelo Biosciences (ARTL) announced new data supporting the therapeutic potential of ART26.12, its proprietary and selective fatty acid binding protein 5 inhibitor, as a novel product candidate for th...
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
Osteoarthritic Pain Model Results Further Validate FABP5 as a Novel Therapeutic Target in Pain Management Osteoarthritic Pain Model Results Further Validate FABP5 as a Novel Therapeutic Target in Pain...
Artelo Biosciences Proxy statement: Proxy filing
Artelo Biosciences filed a proxy statement on July 16, 2026, providing details for shareholder voting and corporate governance matters.
Artelo Biosciences Proxy statement: Proxy filing
Artelo Biosciences filed a proxy statement on July 16, 2026, providing details for shareholder voting and corporate governance matters.
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026
Every proxy submitted helps establish the quorum needed to conduct the Company's Annual Meeting, regardless of how shareholders choose to vote Every proxy submitted helps establish the quorum needed t...
Artelo Biosciences announces results from ART27.13 nonclinical studies
Artelo Biosciences (ARTL) announced results from nonclinical studies in neuropathic pain with ART27.13, the company’s proprietary peripherally restricted cannabinoid receptor agonist, currently in Pha...
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
Expands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer
Artelo Biosciences Proxy statement: Proxy filing
Artelo Biosciences filed a proxy statement on July 2, 2026, providing details for shareholder voting and corporate governance matters.
Artelo Biosciences presents preclinical pain data for ART26.12
Artelo Biosciences (ARTL) announced positive new data from a preclinical study in neuropathic pain from spinal cord injury. Conducted in collaboration with Stony Brook University, the study showed tha...
Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury
The nonclinical study conducted at Stony Brook University adds to substantial evidence of activity across multiple animal models of neuropathic pain The nonclinical study conducted at Stony Brook Univ...
Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026
Multi-omics analyses identifies linoleic acid as a critical fatty acid which is modulated by ART26.12 Multi-omics analyses identifies linoleic acid as a critical fatty acid which is modulated by ART26...
Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026
First-in-Human Results Demonstrate Favorable Safety and Pharmacokinetics Profile AI Aided Target Engagement Research Advancing Development of Novel Biomarkers SOLANA BEACH, Calif., June 29, 2026 (GLOB...
Artelo Biosciences Proxy statement: Proxy filing
Artelo Biosciences filed a proxy statement on June 22, 2026, providing details for shareholder voting and corporate governance matters.